EXCELINDUS Excel Industries Q4 FY25 results (Jan–Mar 2025) and concall
Excel Industries delivered strong financial performance in Q4 and FY25, marked by significant revenue and EBITDA growth driven by improved demand and product mix. The company is strategically investing in capacity expansion for biocides, establishing a new R&D center, and commencing a long-term supply contract to drive future growth. While navigating a volatile market, Excel maintains a focus on operational efficiency and strengthening its core phosphorus chemistry business while diversifying into specialty chemicals.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 269 | 196 | 248 |
| EBITDA | 49 | 12 | 20 |
| Net profit | 34 | 6 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
